Alvotech (ALVO) Stock Price, News & Analysis

Company Overview

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology.

Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

Key Stats

• Today's Range: $4.16 to $4.63
• 50-Day Range: $4.48 to $6.15
• 52-Week Range: $2.94 to $6.53
• Volume: 1.29 million shs
• Average Volume: 779,029 shs
• Market Capitalization: $1.28 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.40
• Consensus Rating: Hold

Alvotech Stock Analysis - MarketRank™

Alvotech scored higher than 66% of companies evaluated by MarketBeat, and ranked 275th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Alvotech has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Alvotech has a consensus price target of $8.40, representing about 99.3% upside from its current price of $4.21.

Amount of Analyst Coverage

Alvotech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alvotech are expected to grow in the coming year, from ($0.01) to $0.22 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alvotech is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alvotech is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.05% of the float of Alvotech has been sold short.

Short Interest Ratio / Days to Cover

Alvotech has a short interest ratio ("days to cover") of 8.26.

Change versus previous month

Short interest in Alvotech has recently decreased by 2.83%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alvotech does not currently pay a dividend.

Dividend Growth

Alvotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.44

News Sentiment

Alvotech has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Alvotech this week, compared to 7 articles on an average week.

Search Interest

3 people have searched for ALVO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added Alvotech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alvotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.46% of the stock of Alvotech is held by insiders.

Percentage Held by Institutions

Alvotech has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/11/2026
• Today: 11/13/2026
• UBS Global Biopharma Conference 2026: 11/17/2026
• Jefferies Global Healthcare Conference: 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALVO
• Previous Symbol: NYSE:ALVO
• CIK: 1898416
• Web: www.alvotech.com
• Phone: 354-422-4500
• Fax: N/A
• Employees: 1,460
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Alvotech: $8.40
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +97.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 19.32
• P/E Growth: N/A
• Net Income: $27.92 million
• Net Margins: -50.62%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -11.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $588.90 million
• Price / Sales: 2.18
• Cash Flow: $0.19 per share
• Price / Cash Flow: 22.58
• Book Value: ($0.94) per share
• Price / Book: -4.52

Miscellaneous

• Outstanding Shares: 301,810,000
• Free Float: 300,418,000
• Market Cap: $1.28 billion
• Optionable: Not Optionable
• Beta: 0.24